RGPU-95

RGPU-95 is a laboratory research compound belonging, by its chemical relationship, to the racetam family of nootropics ^[1]. It was designed as a structural analog of fenotropil, the Russian nootropic also known as phenylpiracetam or fonturacetam, and it comes from the same tradition of Russian medicinal-chemistry research that produced a series of experimental molecules identified by RGPU code numbers ^[1]. Published information on RGPU-95 is very limited and confined to Russian scientific literature; it has not entered mainstream international pharmacology.

The main published study of RGPU-95 examined its effects on anxiety and depression-related behaviour in rats, comparing it with fenotropil and with reference drugs ^[1]. Both fenotropil and RGPU-95 reduced anxious and depressive behaviour more strongly in male than in female animals ^[1]. In that work RGPU-95's anti-anxiety effect was reported to exceed that of fenotropil, though it remained weaker than the benzodiazepine diazepam, while its antidepressant effect was comparable to the classic antidepressant imipramine and greater than that of fenotropil ^[1]. These findings come from animal models only, and there is no published clinical evidence in humans.

Because RGPU-95 is defined by its relationship to phenylpiracetam, the better-characterized properties of that parent compound provide context ^[2]. Phenylpiracetam is a phenyl-substituted derivative of the original nootropic piracetam, credited with nootropic, anti-asthenic, anxiolytic, antidepressant, anticonvulsant, and anti-inflammatory actions in experimental and clinical studies, and it has been investigated in conditions such as cerebral ischemia, asthenia, and mental disorders ^[2]. Phenylpiracetam is a licensed medicine in Russia and some neighbouring countries but is not approved in most of the world, and it was the first nootropic banned in sport, prohibited under the name carphedon, later fonturacetam, in 1998 ^[2][3]. RGPU-95 has not undergone this kind of development and remains a preclinical curiosity.

RGPU-95 is not an approved drug in any country and is not an established dietary supplement ingredient; it exists essentially as an experimental substance described in a small body of Russian research ^[1]. Compounds of this type illustrate a broader pattern in which obscure nootropic molecules, some derived from Russian pharmacology, circulate at the margins of the supplement market despite lacking regulatory approval and adequate human safety data ^[3]. Anyone encountering RGPU-95 should treat it as an unstudied research chemical rather than a proven medicine ^[1][3].

Treat this as a true unknown. RGPU-95 is a novel research chemical with no human trials, no approvals anywhere, and no established dose; all the evidence is Russian animal work. Because it behaves like a stronger phenylpiracetam, expect stimulant-style risks; overstimulation, insomnia, headache, blood-pressure and heart-rate bumps, and fast tolerance if used daily. Being far more potent than phenylpiracetam, the margin for a heavy dose is smaller, so more is genuinely riskier here. Phenylpiracetam is banned in sport (WADA), and this analog would carry the same problem. Do not mix casually with stimulants, MAOIs or serotonergic drugs given the dopamine and mood activity. No pregnancy, cardiac or long-term data exists.

RGPU-95, also referred to as para-chlorophenylpiracetam or p-Cl-phenylpiracetam, is a synthetic analogue of phenylpiracetam bearing a chlorine substitution on the phenyl ring. It was developed by Russian pharmacologists at Volgograd State Medical University as part of a program investigating structural analogues of phenylpiracetam in the search for improved nootropic and psychotropic activity, and it was described in the scientific literature around 2010. The work situated RGPU-95 within a broader Russian tradition of racetam research aimed at compounds with combined cognitive and anxiolytic or antidepressant properties.

RGPU-95 is a niche and experimental compound that is known mainly to nootropic enthusiasts and to a handful of research-chemical vendors who market it as a more potent relative of phenylpiracetam. Preclinical Russian studies reporting anxiolytic and antidepressant activity, and claims of greater potency than the parent compound, underpin much of its appeal, but it lacks the independent clinical research and long track record of established nootropics. As a result it is generally viewed as an intriguing but poorly validated option carrying the usual uncertainties of a compound characterized almost entirely in animal models.